Want to see LENZ full AI Analyst Report?
LENZ Stock Chart & Stats
$4.81
$0.43(8.51%)
At close: 4:00 PM EDT
$4.81
$0.43(8.51%)
Day’s Range― - ―
52-Week Range$3.12 - $34.27
Previous CloseN/A
Volume1.43M
Average Volume (3M)770.30K
Market Cap
$101.17M
Enterprise Value-$41.23M
Total Cash (Recent Filing)$220.00M
Total Debt (Recent Filing)$122.00K
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Oct 29, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend Yield89.01%
Share Statistics
EPS (TTM)-4.09
Shares Outstanding31,420,343
10 Day Avg. Volume749,015
30 Day Avg. Volume770,301
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)1.62
Price to Sales (P/S)24.15
P/FCF Ratio-6.59
Enterprise Value/Market Cap-0.41
Enterprise Value/Revenue-1.92
Enterprise Value/Gross Profit-2.13
Enterprise Value/Ebitda0.33
Forecast
1Y Price Target
$22.00Price Target Upside357.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.11
Revenue Forecast (FY)$16.72M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginRapid revenue growth alongside approximately 90% gross margin indicates improving product traction and attractive underlying economics. If commercial adoption continues, the margin structure could allow incremental sales to contribute meaningfully toward operating costs and support a more scalable business model.
Low Leverage And Capital BaseMinimal debt and a sizable positive equity base reduce solvency pressure and preserve financial flexibility while the company develops its commercial platform. This structure limits interest burden and provides more capacity to allocate capital toward growth initiatives than a highly leveraged balance sheet would allow.
Patient Persistence And AdoptionRepeat purchasing is an important early indicator that VIZZ may deliver durable patient value rather than relying solely on initial trial. Stronger persistence can improve lifetime revenue per patient, make commercial spending more productive, and support recurring demand as the launch matures.
Bears Say
Heavy Cash BurnThe substantial operating and free cash outflows show that the current business is not yet self-funding. Continued burn can consume the company’s capital base before product revenue reaches sufficient scale, increasing dependence on future financing or tighter spending decisions to sustain operations.
Large Operating LossesDeep operating losses remain disproportionate to the company’s current revenue base, showing that commercialization has not yet produced operating leverage. Unless revenue expands substantially or expenses are reduced, persistent losses will continue to weigh on capital efficiency and delay a path to profitability.
Limited Retail ConversionWeak retail uptake limits the breadth of the commercial channel and makes overall demand less diversified beyond e-pharmacy. It also reduces visibility into recurring behavior among retail patients, which can constrain forecasting, weaken marketing efficiency, and slow the transition to broader market penetration.
LENZ Therapeutics News
LENZ FAQ
What was LENZ Therapeutics’s price range in the past 12 months?
LENZ Therapeutics lowest stock price was $3.12 and its highest was $34.27 in the past 12 months.
What is LENZ Therapeutics’s market cap?
LENZ Therapeutics’s market cap is $101.17M.
When is LENZ Therapeutics’s upcoming earnings report date?
LENZ Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 7 days.
How were LENZ Therapeutics’s earnings last quarter?
LENZ Therapeutics released its earnings results on Aug 11, 2026. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.05 by $0.03.
Is LENZ Therapeutics overvalued?
According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued.
Does LENZ Therapeutics pay dividends?
LENZ Therapeutics pays a Weekly dividend of $7.21 which represents an annual dividend yield of 89.01%. See more information on LENZ Therapeutics dividends here
What is LENZ Therapeutics’s EPS estimate?
LENZ Therapeutics’s EPS estimate is -0.89.
How many shares outstanding does LENZ Therapeutics have?
LENZ Therapeutics has 31,420,343 shares outstanding.
What happened to LENZ Therapeutics’s price movement after its last earnings report?
LENZ Therapeutics reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.05. Following the earnings report the stock price went down -3.263%.
Which hedge fund is a major shareholder of LENZ Therapeutics?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.00 (357.38% Upside)
$22.00 (357.38% Upside)
Blogger Sentiment
Neutral
LENZ Sentiment 67%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.40%
12-Months-Change
Fundamentals
Return on Equity
-53.39%
Trailing 12-Months
Asset Growth
8.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
LENZ Therapeutics
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
LENZ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of encouraging commercial signals and meaningful operational/financial challenges. Positive indicators include strong early patient persistence in the e‑pharmacy channel (60%+ repeat purchasers and mature cohorts trending to ~5 packs/year), a notable >45% month‑over‑month script lift in July after launching telehealth and national TV, expanding global partnerships and multiple regulatory submissions, and a strong cash balance (~$220M) with an expected high direct product gross margin (~90%). Offsetting these positives are modest product revenue ($1.7M) relative to high operating expenses (Q2 net loss $31.9M; SG&A $39.4M), limited retail channel pickup and visibility, and the caveat that July’s improvement is an early one‑month signal that may not yet represent a durable trend. Management emphasized discipline in capital allocation and a data‑driven reallocation of commercial spend to activities that demonstrably drive durable patient growth.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$22.00
▲(357.38% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Vivani Medical
―
Outlook Therapeutics
―
Kalaris Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
6.75% Insiders
15.84% Mutual Funds
0.07% Other Institutional Investors
68.27% Public Companies and
Individual Investors